Against 482 obligate anaerobes studied by the agar dilution technique, ceftizoxine was significantly more active than both cefoxitin and cefoperazone (P < 0.001); the latter two agents were comparable in activity. The enhanced activity of ceftizoxime, as compared with the activity of cefoxitin, was against both grampositive and gram-negative anaerobes (especially Lactobacillus and Bacteroides spp.). Cefoperazone, however, was more active than cefoxitin against gram-positive anaerobes (particularly Lactobacillus spp.) but was less active than cefoxitin against gram-negative anaerobes (particularly Bacteroides fragilis and Veillonella spp.).
Ceftizoxime (FK-749) and cefoperazone are two newer cephalosporins with enhanced in vitro activity against a wide variety of gram-positive and gram-negative organisms, including nosocomial pathogens such as Serratia and Enterobacter spp. (6, 7) . Both antimicrobial agents exhibit stability to beta-lactamase activity, although ceftizoxime has been reported to be more stable than cefoperazone to beta-lactamase hydrolysis (1, 9) . Their in vitro activities against clinically important anaerobic bacteria, however, have not been extensively investigated (1, 3, 5, 7, 8) . We report here the in vitro activities of ceftizoxime and cefoperazone against 482 isolates of anaerobic bacteria, as determined by an agar dilution technique; the activities of both agents were compared with that of cefoxitin. jig/ml) (P < 0.001), whereas cefoperazone (geometric mean MIC, 1.81 ,g/ml) was comparable to cefoxitin. At concentrations readily achieved in serum for these antibiotics (16 pg/ml), similar cumulative percentages of the total number of isolates were inhibited by ceftizoxime (85%), cefoperazine (80%), and cefoxitin (85%).
Considerable variation in susceptibility was observed for each antibiotic among different genera or species of anaerobes tested. Among Bacteroides spp., B. fragilis was more resistant than B. vulgatus (P < 0.001) but more susceptible than B. corrodens (P < 0.001) and was comparable in activity to B. ruminicola for all three antibiotics. B. fragilis was more resistant than B. distasonis to ceftizoxime (P < 0.001), whereas B. fragilis was more susceptible than B. thetaiotaomicron (P < 0.001) to cefoxitin. Among anaerobic cocci, Veillonella spp. were more resistant than Peptococcus spp. (P < 0.001) to cefoperazone and cefoxitin, whereas no significant difference in resistance to ceftizoxime was noted. Among gram-positive bacilli, C. perfringens was consistently more susceptible than non-perfringens species of Clostridia to all three antibiotics (P < 0.001). Similarly, Lactobacillus spp. were consistently more resistant than other non-spore-forming anaerobic gram-positive bacilli (Propionibacterium, Bifidobacterium, Eubacterium, and Actinomyces spp.) to all three antibiotics (P < 0.005).
The comparative in vitro activities of these agents indicated that ceftizoxime was more active overall than cefoxitin (P < 0.001), and this enhanced activity was against both gram-positive (particularly Lactobacillus spp.) and gramnegative anaerobes (particularly Bacteroides spp.) (P < 0.005). Cefoperazone, on the other hand, was more active than cefoxitin against gram-positive anaerobes (particularly Lactobacillus spp.; P < 0.001) but was less active than cefoxitin against gram-negative anaerobes (particularly B. fragilis and Veillonella spp.; P < 0.005). The enhanced in vitro activities of these newer cephalosporins, particularly ceftizoxime, NOTES 685 against a wide variety of anaerobic bacteria, coupled with their broadened activity against many aerobic organisms, offers considerable promise for their use in single-agent therapy for mixed aerobic-anaerobic infections. Controlled clinical trials are indicated.
